p300 (F-4) Antibody from Santa Cruz Biotechnology, Inc.

Yes, the p300 (F-4) antibody has been utilized in studies investigating the interaction of p300 with phosphorylated STAT3, which is crucial for TH17 cell differentiation. For instance, it was shown that p300 interacts with Smad2 and STAT3 to transactivate genes involved in this process, highlighting its role as a co-activator in TH17 differentiation (yoon2015).

The p300 (F-4) antibody has been successfully used in immunohistochemistry, as demonstrated in studies assessing p300 expression in clinical tumor samples. It was employed to evaluate histopathological changes and epigenetic modifications in various tissues, indicating its suitability for this application (li2024; terada2022).

The p300 antibody has been used to explore its role in enhancing the sensitivity of pituitary adenomas to dopamine agonist treatment by regulating the transcription of the dopamine D2 receptor (DRD2). This research suggests that p300's acetyltransferase activity is critical for overcoming drug resistance in cancer therapies (li2024).

The p300 (F-4) antibody is reactive with mouse, human, and rat species. It has been cited in numerous studies, including those examining its role in chromatin remodeling and gene transcription regulation, confirming its utility across different biological contexts (chen2018; dhar2022).